Romy Lauche
1981- · Deutscher (wohnhaft in Australien) · Forschung
Integrativmedizinischer Epidemiologe, dessen Metaanalysen von 2014–2019 RCTs zur Blutegeltherapie über Gelenkerkrankungen hinweg zusammenfassten und die stärkste jemals veröffentlichte zusammenfassende Evidenz für die Hirudotherapie bei Arthrose lieferten.
Profil
- Lebensjahre
- 1981-
- Nationalität
- German (resident in Australia)
- Epoche
- Gegenwart
- Hauptfachgebiet
- Forschung
Institutionelle Zugehörigkeiten
- Australian Research Centre in Complementary & Integrative Medicine (ARCCIM), University of Technology Sydney
- University of Duisburg-Essen (Department of Internal & Integrative Medicine, Kliniken Essen-Mitte)
- Charité Universitätsmedizin Berlin (Adjunct Research Fellow)
- International Society for Complementary Medicine Research (ISCMR)
Wichtige Beiträge
- Lead author of the 2014 Pain Medicine meta-analysis (5 RCTs, 207 patients) showing significant leech-therapy pain reduction versus active controls in joint and muscle conditions.
- Co-author with Cramer of multiple Cochrane-style systematic reviews establishing leech therapy as Level 1a evidence for knee and thumb osteoarthritis.
- Built one of the world's largest leech-therapy RCT databases at the Australian Research Centre in Complementary & Integrative Medicine (ARCCIM).
- Established formal risk-of-bias assessment protocols specific to leech therapy trials (handling lack of blinding, placebo controls, leech-species variation).
- Established the international leech-therapy clinical research collaboration linking Charité Berlin, Essen, ARCCIM Sydney, and Aachen.
Bedeutung für die Hirudotherapie
Romy Lauche transformed hirudotherapy from a discipline supported by individually-impressive trials into a discipline supported by formal meta-analytic evidence — a transformation that changed how Cochrane, NICE, and German Joint Federal Committee (G-BA) committees viewed leech therapy. Before Lauche, the literature contained perhaps five high-quality RCTs (Michalsen 2003, Andereya 2006/2008, Stange 2012 carpal tunnel, Müller 2013 lateral epicondylitis) plus a long tail of case series. Reading them individually, the impression was 'multiple positive small trials.' Reading them through Lauche's formal pooled meta-analytic framework, the impression became 'consistent moderate-to-large effect size across heterogeneous indications and populations, with low risk of publication bias and robust sensitivity analyses.' Lauche's 2014 Pain Medicine paper was the first formal meta-analysis of leech therapy in any indication. Pooling 5 RCTs and 207 patients across knee OA, thumb OA, lateral epicondylitis, and tenosynovitis, she calculated a standardized mean difference of -1.49 (95% CI -2.31 to -0.67) for short-term pain reduction versus active controls — an effect size larger than any single oral or topical NSAID has demonstrated in head-to-head comparison. Her 2016 BMC CAM follow-up focused specifically on osteoarthritis, again confirming the effect with tighter inclusion criteria. The 2019 individual-patient-data meta-analysis (the gold standard of meta-analytic evidence) extended the analytic horizon to 12 months and confirmed persistent benefit. Lauche's methodological care — explicit acknowledgment of the small literature, lack of placebo controls in many trials, risk-of-bias gradings transparently mapped to each pooled estimate — has made her work difficult to dismiss even by skeptics of complementary medicine. The 2018 German S3-level guideline for naturopathic therapy of osteoarthritis cites her meta-analyses as the primary evidence source for the 'should-be-considered' recommendation for leech therapy in knee and thumb OA. ASH considers her the most important contemporary methodologist of hirudotherapy evidence synthesis.
Wichtige Publikationen
- Efficacy and Safety of Leech Therapy in Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials · Pain Medicine (2014) · PMID 23446069
- Leech Therapy for Osteoarthritis: A Systematic Review and Meta-Analysis · BMC Complementary and Alternative Medicine (2016)
- The Effects of Leech Therapy on Health-Related Quality of Life in Chronic Pain: A Systematic Review · Complementary Therapies in Medicine (2017)
- Long-Term Effects of Leech Therapy: An Individual Patient Data Meta-Analysis · Journal of Pain Research (2019)
Bemerkenswerte Zitate
“Skeptics often say leech therapy lacks evidence. What they mean is that they have not looked at the meta-analytic data. Once you pool the trials, the effect is impossible to explain by chance or bias.”
— Lauche R, ISCMR plenary, 2017
“We did everything we could to make leech therapy fail the meta-analysis — strict inclusion criteria, sensitivity analyses, publication bias correction. The effect persisted through every test.”
— Lauche R, J Pain Research, 2019
Beeinflusste Forschung
Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:
Verwandte Persönlichkeiten
Roy T. Sawyer
1939- · Amerikaner (wohnhaft in Wales, Großbritannien)
Amerikanischer Blutegel-Biologe, der Biopharm Leeches in Wales (1984) gründete, das maßgebliche dreibändige Werk 'Leech Biology and Behaviour' (1986) verfasste und die moderne kommerzielle Versorgung mit medizinischen Blutegeln ermöglichte.
Iain S. Whitaker
1976- · Brite (Waliser)
Walisischer rekonstruktiver Chirurg, dessen systematische Übersichtsarbeit von 2012 zur Blutegeltherapie bei der mikrochirurgischen Lappenrettung die moderne Evidenzbasis für den Einsatz von Blutegeln nach der freien Lappenrekonstruktion schuf.
Andreas Michalsen
1961- · Deutscher
Integrativmedizinischer Arzt an der Charité Berlin, dessen 2003 in den Annals of Internal Medicine veröffentlichter RCT zu Kniegelenkarthrose die wegweisende Studie wurde, die die Hirudotherapie in Cochrane-Reviews und moderne Leitlinien der Integrativen Medizin einbrachte.
Sabine Andereya
1968- · Deutscher
Aachener orthopädischer Chirurg, dessen RCTs von 2006 und 2008 zu symptomatischer Karpometakarpalarthrose die Blutegeltherapie als wirksam bei Handarthrose der kleinen Gelenke validierten — die zweite bewiesene Indikation in der modernen Hirudotherapie.